Page contentsPage contents Key facts Decision Key facts Active substance Ifinatamab deruxtecan Therapeutic area Gastrointestinal disorders Decision number EMA/PE/0000232638 PIP number EMA/PE/0000232638 Pharmaceutical form(s) All pharmaceutical forms Condition(s) / indication(s) Treatment of oesophageal cancer Route(s) of administration All routes of administration Contact for public enquiries Daiichi Sankyo Europe GmbH E-mail: service@daiichi-sankyo.euTel.: +49 8978080 Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 21/03/2025 Compliance check done No Decision EMA/PE/0000232638 : EMA decision of 21 March 2025 on the granting of a product specific waiver for ifinatamab deruxtecanAdopted Reference Number: EMADOC-1700519818-1975290 English (EN) (240.75 KB - PDF)First published: 04/06/2026 View Share this page